A Phase 1 Study of PNT2258 in Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 01 Feb 2017
At a glance
- Drugs Rosomidnar (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors ProNAi Therapeutics
- 09 Nov 2012 Results were presented at the the annual EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, according to a ProNai Therapeutics media release.
- 09 Nov 2012 Status changed from recruiting to completed, as reported in a ProNAi Therapeutics media release.
- 04 Jun 2012 The ten planned dose cohorts have been completed.